Overview Technical Risk & rank Results Accounts Filings Guidance & governance
Guidance tracker
What RAINBOW guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 06 Nov 2026 | Rainbow Children's Medicare filed the transcript of its Q2 FY27 earnings conference call held on November 2, 2026, covering unaudited results for the quarter and half year ended September 30, 2026. Management reported Q2 operating revenue of INR 548 crores (up 23.2% year-on-year), EBITDA of INR 170 crores (up... NSE copy | No results filed since | ||
| 04 Aug 2026 | Rainbow Children's Medicare filed the transcript of its Q1 FY27 investor/earnings call held on July 31, 2026, for the quarter ended June 30, 2026. Management reported operating revenue of INR 470 crores, up 33% year-on-year, and EBITDA of INR 134.6 crores, up 30% year-on-year, with an EBITDA margin of 28.6%. Profit... NSE copy | +9.1 % | +23.2 % | +1.7 % |
| 01 Jun 2026 | Rainbow Children's Medicare filed the transcript of its Q4 & FY26 investor call held on May 25, 2026 (link to the transcript on the company website provided). Management said Q4 FY26 revenue was INR 459.9 crores (up 24% YoY), EBITDA INR 144.7 crores (up 26%), PAT INR 78.2 crores (up 38%; about 17% excluding... NSE copy | +13.2 % | +33.2 % | +0.3 % |
| 03 Feb 2026 | Rainbow Children's Medicare filed the transcript of its Q3 FY26 and 9M FY26 investor call held on January 29, 2026. Management reported Q3 FY26 revenue of INR445.4 crores (up 12%), EBITDA of INR147 crores (up 9%) and PAT of INR73.9 crores (up 7%); occupancy was 47.2% for the quarter. For 9M FY26, revenue was... NSE copy | - | - | -0.4 % |
| 20 Nov 2025 | Rainbow Children's Medicare filed the transcript of its Q2 & H1 FY26 investor call held on November 14, 2025. Management reported Q2 FY26 operating revenue of Rs.444.8 Crores (up 6.5% YoY), EBITDA of Rs.148.8 Crores (up 1.2%, margin 33.5%) and PAT of Rs.75.6 Crores (down 4.3%). For H1 FY26, management reported... NSE copy | +5.6 % | +11.9 % | -0.3 % |
| 04 Aug 2025 | Rainbow Children's Medicare filed the transcript of its Q1 FY26 investor call held on July 28, 2025, under Regulation 30. Management said revenue grew 7% to INR353 crores, EBITDA rose 11% to INR103.6 crores (29.4% margin), and PAT rose 35% to INR53.8 crores; occupancy was 40.2%. Management said it acquired a 76%... NSE copy | -4.6 % | +6.5 % | -1.0 % |
| 31 May 2025 | Rainbow Children's Medicare filed the transcript of its Q4 FY25 earnings investor call held on May 26, 2025. Management said Q4 revenue grew 8.5% to INR 370.1 crores, EBITDA rose 8.7% to INR 114.7 crores and PAT grew 10.7% to INR 56.5 crores; full-year revenue was INR 1,515.9 crores (up 16.9%) and full-year PAT INR... NSE copy | +35.3 % | +6.9 % | -1.0 % |
| 15 Feb 2025 | Rainbow Children's Medicare filed the transcript of its Q3 & 9M FY25 investor call held on February 10, 2025. Management reported Q3 FY25 revenue of INR398 crores (up 18.5%), EBITDA of INR134.3 crores (up 14%) and PAT of INR68.9 crores (up 10.2%); 9M revenue was INR1,146 crores (up about 20%) and 9M PAT INR188... NSE copy | +35.3 % | +6.9 % | -1.0 % |
Filings tagged as guidance, newest first (8 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 29 Sep 2026 | Credit rating | Rainbow Children's Medicare Limited filed an intimation under SEBI LODR Regulation 30 on September 29, 2026 regarding a credit rating action. ICRA Limited has reaffirmed the company's issuer rating at [ICRA]AA (Stable). The filing states this is a reaffirmation of the rating assigned last time. The rating will... NSE copy |
| 23 Sep 2026 | Legal or regulatory, Management change | Rainbow Children's Medicare Limited filed the outcome of its board meeting held on September 23, 2026. The board appointed Mr. Sudarshan Patodia as Chief Financial Officer and Key Managerial Personnel, designated Group Chief Financial Officer, effective September 23, 2026. Mr. Patodia is a Chartered Accountant with... NSE copy |
| 30 Jul 2026 | Management change | Outcome of board meeting held July 30, 2026: board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a limited review report from statutory auditors S.R. Batliboi & Associates LLP. Standalone revenue from operations for Q1 FY27 was Rs 4,105.47 million,... NSE copy |
| 30 Jul 2026 | Management change | Board of Rainbow Children's Medicare Limited approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with limited review report from S.R. Batliboi & Associates LLP. Standalone revenue from operations for Q1 FY27 was Rs 4,105.47 million, up from Rs 3,347.48 million a... NSE copy |
| 23 May 2026 | Legal or regulatory, Management change | Outcome of board meeting held May 23, 2026: audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 approved, with unmodified audit opinion from S.R. Batliboi & Associates LLP. Final dividend of ₹3.5 per equity share (35% on face value of ₹10) recommended for FY 2025-26,... NSE copy |
| 23 May 2026 | Legal or regulatory, Management change | Board of Rainbow Children's Medicare Limited, meeting held May 23, 2026, approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with unmodified audit opinions from S.R. Batliboi & Associates LLP. Board recommended a final dividend of ₹3.5 per equity share (35%... NSE copy |
| 03 Feb 2026 | Management change | Rainbow Children's Medicare filed the transcript of its Q3 FY26 and 9M FY26 investor call held on January 29, 2026. Management reported Q3 FY26 revenue of INR445.4 crores (up 12%), EBITDA of INR147 crores (up 9%) and PAT of INR73.9 crores (up 7%); occupancy was 47.2% for the quarter. For 9M FY26, revenue was... NSE copy |
| 28 Jan 2026 | Management change | Rainbow Children's Medicare Limited filed the outcome of its board meeting held January 28, 2026, approving unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, with a limited review report from statutory auditors S.R. Batliboi & Associates LLP. Standalone... NSE copy |
| 20 Nov 2025 | Management change | Rainbow Children's Medicare filed the transcript of its Q2 & H1 FY26 investor call held on November 14, 2025. Management reported Q2 FY26 operating revenue of Rs.444.8 Crores (up 6.5% YoY), EBITDA of Rs.148.8 Crores (up 1.2%, margin 33.5%) and PAT of Rs.75.6 Crores (down 4.3%). For H1 FY26, management reported... NSE copy |
| 13 Nov 2025 | Management change | Rainbow Children's Medicare Limited filed the outcome of its board meeting held November 13, 2025, approving unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. Standalone revenue from operations for Q2 FY26 was Rs 4,084.96 million, against Rs 4,039.25... NSE copy |
| 14 Aug 2025 | Credit rating | Rainbow Children's Medicare Limited filed a Regulation 30 disclosure on August 14, 2025 forwarding a credit rating letter received that day from ICRA Limited. ICRA reaffirmed the company's issuer rating at [ICRA]AA (Stable). The letter states the rating is due for surveillance within one year from the date of the... NSE copy |
| 26 Jul 2025 | Management change | Rainbow Children's Medicare Limited filed the outcome of its board meeting held July 26, 2025, approving unaudited standalone and consolidated results for the quarter ended June 30, 2025. Standalone revenue from operations for Q1 FY26 was Rs. 3,347.48 million, against Rs. 3,150.23 million in the year-ago quarter... NSE copy |
| 26 Jul 2025 | Management change | Board of Rainbow Children's Medicare Limited approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with a limited review report from S.R. Batliboi & Associates LLP. Standalone revenue from operations for Q1 FY26 was Rs 3,347.48 million, against Rs 3,150.23 million... NSE copy |
| 09 Feb 2025 | Management change | Board of Rainbow Children's Medicare Limited met on February 9, 2025 and approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with Limited Review Reports from statutory auditors S. R. Batliboi & Associates LLP. The Board appointed Ms. Shreya Mitra... NSE copy |
| 09 Feb 2025 | Legal or regulatory, Management change | Board of Rainbow Children's Medicare Limited approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with limited review reports from S. R. Batliboi & Associates LLP enclosed. Board appointed Ms. Shreya Mitra (ICSI Membership No: A54901) as Company... NSE copy |
| 07 Jan 2025 | Credit rating | Rainbow Children's Medicare Limited filed a credit rating disclosure under Regulation 30 of the SEBI LODR Regulations, dated January 7, 2025. ICRA Limited reaffirmed the company's issuer rating at [ICRA]AA (Stable), the same rating as assigned previously. The rated amount is shown as Rs. 0.00 crore, with the rating... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (16 in all). A list of what was filed, not a judgement of the company.